Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers

Oncotarget

Volumn 3, Issue 9, 2012, Pages 988-997

  Perez, Roberto ^a,b,c   Schally, Andrew V ^a,b,c   Vidaurre, Irving ^a,b   Rincon, Ricardo ^a,b   Block, Norman L ^a,c   Rick, Ferenc G ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b South Florida VA Foundation for Research and Education   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammation; Neuropeptide analog; Receptor silencing; Targeted therapy; Tumor gene expression

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; GROWTH HORMONE RELEASING HORMONE ANTAGONIST; HORMONE ANTAGONIST; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MIA 602; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

EID: 84868624948     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.634     Document Type: Article

References (50)

1. CDC. (2010). Centers for Disease Control and Prevention: US Incidence of Breast Cancers.
2. Dawson SJ, Provenzano E and Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer. 2009; 45 Suppl 1(19775602): 27-40.
3. Bartsch R, Ziebermayr R, Zielinski CC and Steger GG. Triple-negative breast cancer. Wien Med Wochenschr. 2010; 160(20473728): 174-181.
4. Gerger A, Renner W, Langsenlehner T, Hofmann G, Knechtel G, Szkandera J, Samonigg H, Krippl P and Langsenlehner U. Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat. 2010; 119(19437115): 701-705.
5. Tawara K, Oxford JT and Jorcyk CL. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res. 2011; 3(21625400): 177-189.
6. Zhao X, Sun X, Gao F, Luo J and Sun Z. Effects of ulinastatin and docataxel on breast tumor growth and expression of IL-6, IL-8, and TNF-alpha. J Exp Clin Cancer Res. 2011; 30(1): 22.
7. Pradhan M, Bembinster LA, Baumgarten SC and Frasor J. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements. J Biol Chem. 2010; 285(41): 31100-31106.
8. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM and Hall BM. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene. 2009; 28(19581928): 2940-2947.
9. Iliopoulos D, Hirsch HA, Wang G and Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A. 2011; 108(21220315): 1397-1402.
10. Guo W, Lasky JL, Chang C-J, Mosessian S, Lewis X, Xiao Y, Yeh JE, Chen JY, Iruela-Arispe ML, Varella-Garcia M and Wu H. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature. 2008; 453(18463637): 529-533.
11. Lopez-Novoa JM and Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med. 2009; 1(6-7): 303-314.
12. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED and Thompson EW. Epithelial--mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol. 2007; 213(2): 374-383.
13. Hohla F and Schally AV. Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer. Cell Cycle. 2010; 9(9): 1738-1741.
14. Rick FG, Buchholz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Aigner E, Perez R, Seitz S, Block NL and Hohla F. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell Cycle. 2012; 11(13): 2518-2525.
15. Szepeshazi K, Schally AV, Keller G, Block NL, Benten D, Halmos G, Szalontay L, Vidaurre I, Jaszberenyi M and Rick FG. Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108]. Oncotarget. 2012; 3(7): 686-699.
16. Schally AV, Varga JL and Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab. 2008; 4(1): 33-43.
17. Barabutis N and Schally AV. Growth hormone-releasing hormone: extrapituitary effects in physiology and pathology. Cell Cycle. 2010; 9(20): 4110-4116.
18. Varga JL, Schally AV, Horvath JE, Kovacs M, Halmos G, Groot K, Toller GL, Rekasi Z and Zarandi M. Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10. Proc Natl Acad Sci U S A. 2004; 101(14755056): 1708-1713.
19. Szereday Z, Schally AV, Varga JL, Kanashiro CA, Hebert F, Armatis P, Groot K, Szepeshazi K, Halmos G and Busto R. Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma. Cancer Res. 2003; 63(14633721): 7913-7919.
20. Weiss-Messer E, Merom O, Adi A, Karry R, Bidosee M, Ber R, Kaploun A, Stein A and Barkey RJ. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Molecular and Cellular Endocrinology. 2004; 220(1-2): 109-123.
21. Busto R, Schally AV, Varga JL, Garcia-Fernandez MO, Groot K, Armatis P and Szepeshazi K. The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc Natl Acad Sci U S A. 2002; 99(12186980): 11866-11871.
22. Chatzistamou I, Schally AV, Kiaris H, Politi E, Varga J, Kanellis G, Kalofoutis A, Pafiti A and Koutselini H. Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers. Eur J Endocrinol. 2004; 151(15362970): 391-396.
23. Halmos G, Schally AV, Czompoly T, Krupa M, Varga JL and Rekasi Z. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. J Clin Endocrinol Metab. 2002; 87(12364462): 4707-4714.
24. Havt A, Schally AV, Halmos G, Varga JL, Toller GL, Horvath JE, Szepeshazi K, Koster F, Kovitz K, Groot K, Zarandi M and Kanashiro CA. The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci U S A. 2005; 102(16299104): 17424-17429.
25. Keller G, Schally AV, Groot K, Toller GL, Havt A, Koster F, Armatis P, Halmos G, Zarandi M, Varga JL and Engel JB. Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A. 2005; 102(16027368): 10628-10633.
26. Heinrich E, Schally AV, Buchholz S, Rick FG, Halmos G, Mile M, Groot K, Hohla F, Zarandi M and Varga JL. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. Prostate. 2008; 68(16): 1763-1772.
27. Kovacs M, Schally AV, Hohla F, Rick FG, Pozsgai E, Szalontay L, Varga JL and Zarandi M. A correlation of endocrine and anticancer effects of some antagonists of GHRH. Peptides. 2010; 31(10): 1839-1846.
28. Pozsgai E, Schally AV, Hocsak E, Zarandi M, Rick F and Bellyei S. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines. Int J Oncol. 2011; 39(4): 1025-1032.
29. Schally AV. New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res. 2008; 40(5): 315-322.
30. Kiaris H, Schally AV, Varga JL, Groot K and Armatis P. Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci U S A. 1999; 96(26): 14894-14898.
31. Rick FG, Schally AV, Szalontay L, Block NL, Szepeshazi K, Nadji M, Zarandi M, Hohla F, Buchholz S and Seitz S. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci U S A. 2012; 109(5): 1655-1660.
32. Siriwardana G, Bradford A, Coy D and Zeitler P. Autocrine/paracrine regulation of breast cancer cell proliferation by growth hormone releasing hormone via Ras, Raf, and mitogen-activated protein kinase. Mol Endocrinol. 2006; 20(9): 2010-2019.
33. Rekasi Z, Czompoly T, Schally AV and Halmos G. Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci U S A. 2000; 97(19): 10561-10566.
34. Csernus VJ, Schally AV, Kiaris H and Armatis P. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci U S A. 1999; 96(10077643): 3098-3103.
35. Kiaris H, Chatzistamou I, Schally AV, Halmos G, Varga JL, Koutselini H and Kalofoutis A. Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor. Proc Natl Acad Sci U S A. 2003; 100(16): 9512-9517.
36. Siejka A, Barabutis N and Schally AV. GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells. Cell Cycle. 2011; 10(21): 3714-3718.
37. Hohla F, Schally AV, Szepeshazi K, Varga JL, Buchholz S, Koster F, Heinrich E, Halmos G, Rick FG, Kannadka C, Datz C and Kanashiro CA. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proc Natl Acad Sci U S A. 2006; 103(16983095): 14513-14518.
38. Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino ALF and Varga JL. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Proc Natl Acad Sci U S A. 2003; 100(14660794): 15836-15841.
39. Hohla F, Buchholz S, Schally AV, Seitz S, Rick FG, Szalontay L, Varga JL, Zarandi M, Halmos G, Vidaurre I, Krishan A, Kurtoglu M, Chandna S, Aigner E and Datz C. GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle. 2009; 8(19): 3149-3156.
40. Sakamoto K, Hikiba Y, Nakagawa H, Hayakawa Y, Yanai A, Akanuma M, Ogura K, Hirata Y, Kaestner KH, Omata M and Maeda S. Inhibitor of kappaB kinase beta regulates gastric carcinogenesis via interleukin-1alpha expression. Gastroenterology. 2010; 139(1): 226-238 e226.
41. Solt LA, Madge LA, Orange JS and May MJ. Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbeta. J Biol Chem. 2007; 282(12): 8724-8733.
42. Rick FG, Schally AV, Block NL, Nadji M, Szepeshazi K, Zarandi M, Vidaurre I, Perez R, Halmos G and Szalontay L. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci U S A. 2011; 108(21321192): 3755-3760.
43. Rick FG, Szalontay L, Schally AV, Block NL, Nadji M, Szepeshazi K, Vidaurre I, Zarandi M, Kovacs M and Rekasi Z. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. J Urol. 2012; 187(4): 1498-1504.
44. Schally AV, Varga JL and Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nature Clinical Practice Endocrinology & Metabolism. 2008; 4(1): 33-43.
45. Khorram O, Garthwaite M, Grosen E and Golos T. Human uterine and ovarian expression of growth hormone-releasing hormone messenger RNA in benign and malignant gynecologic conditions. Fertil Steril. 2001; 75(11163834): 174-179.
46. Seitz S, Hohla F, Schally AV, Moder A, Engel JB, Horn F, Varga J, Zarandi M, Ortmann O, Koster F and Buchholz S. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist. Oncol Rep. 2008; 20(5): 1289-1294.
47. Koster F, Engel JB, Schally AV, Honig A, Schroer A, Seitz S, Hohla F, Ortmann O, Diedrich K and Buchholz S. Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. Breast Cancer Res Treat. 2009; 116(2): 273-279.
48. Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, Weitzenfeld P, Meshel T, Shabtai E, Gutman M and Ben-Baruch A. Inflammatory mediators in breast cancer: Coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer. 2011; 11(1): 130.
49. Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K, Rekasi Z and Schally AV. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A. 1994; 91(25): 12298-12302.
50. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A and Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7): RESEARCH0034.